Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Market Closed - NSE India S.E. Other stock markets 07:05:05 2026-03-16 am EDT			5-day change	1st Jan Change
886.90 ^INR	-2.10%		-2.42%	-3.00%

Mar. 16	Zydus Lifesciences says Sentynl Therapeutics enters into agreement with PRG S&T	RE
Mar. 16	Zydus Lifesciences Drug Desidustat Approved for Renal Anaemia in China	MT

Transcript : Zydus Lifesciences Limited, Q3 2026 Earnings Call, Feb 10, 2026

Published on 02/10/2026 at 01:35 am EST - Modified on 02/10/2026 at 04:23 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, good day, and welcome to Zydus Lifesciences Limited Quarter 3 FY '26 Earnings Call. Please note this call is being recorded. I

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Zydus Lifesciences Limited

Mar. 16	Zydus Lifesciences says Sentynl Therapeutics enters into agreement with PRG S&T	RE
Mar. 16	Zydus Lifesciences Drug Desidustat Approved for Renal Anaemia in China	MT
Mar. 14	Zydus Lifesciences Limited Announces Desidustat Tablets Approval for Renal Anaemia in China	CI
Mar. 13	China Medical System Holdings Limited Announces Approval of Desidustat Tablets for Renal Anaemia in China	CI
Mar. 13	Indian Markets Tank on Friday Amid US-Iran Tensions, Rising Oil Prices	MT
Mar. 13	Zydus Lifesciences Gets US FDA's Final Approval for Cevimeline Hydrochloride Capsules	MT
Mar. 13	Zydus Lifesciences receives final approval from USFDA for cevimeline hydrochloride capsules 30mg	RE
Mar. 13	Zydus Lifesciences Limited Receives Final Approval from Usfda for Cevimeline Hydrochloride Capsules 30Mg	CI
Mar. 12	Zydus Lifesciences Launches Continuous Glucose Monitoring Devices	MT
Mar. 12	Zydus Lifesciences Limited Launches AI-Powered Continuous Glucose Monitor Diasens and Glucolive	CI
Mar. 10	Agenus Triggers First $20 Million Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs	CI
Mar. 10	Agenus Receives $20 Million Contingent Payment From Zydus Lifesciences Collaboration	MT
Feb. 28	Zydus Lifesciences Limited Receives Final Approvals from USFDA for Ivermectin Tablets USP, 3 Mg and Dapsone Tablets USP, 25 Mg and 100 Mg	CI
Feb. 27	Zydus Lifesciences says successful clinical development of pembrolizumab biosimilar fyb206	RE
Feb. 27	Zydus Lifesciences Limited Announces Successful Clinical Development of Pembrolizumab Biosimilar Fyb206	CI